American Century Companies
VRDN icon

American Century Companies’s Viridian Therapeutics VRDN Stock Holding History

American Century Companies’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,236
Closed -$1.11M – 2886
2025
Q3 		$1.11M Sell
51,236
-53,331
-51% -$962K ﹤0.01% 2271
2025
Q2 		$1.46M Sell
104,567
-18,325
-15% -$249K ﹤0.01% 2141
2025
Q1 		$1.66M Buy
122,892
+9,330
+8% +$159K ﹤0.01% 2064
2024
Q4 		$2.18M Buy
113,562
+85,512
+305% +$1.86M ﹤0.01% 1956
2024
Q3 		$638K Buy
+28,050
New +$459K ﹤0.01% 2389

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

American Century Companies's VRDN Position: Q4 2025 in Review

American Century Companies sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 51,236 shares — an estimated $1.11M sold.

American Century Companies first reported a position in VRDN in Q3 2024 and held it in 5 quarters. The position peaked at $2.18M in Q4 2024. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • American Century Companies reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • American Century Companies sold 51,236 Viridian Therapeutics shares in Q4 2025, an estimated $1.11M.
  • American Century Companies first reported a position in Viridian Therapeutics in Q3 2024 and held it in 5 quarters.
  • American Century Companies's Viridian Therapeutics position peaked at $2.18M in Q4 2024.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on American Century Companies's 13F filing for Q4 2025, filed 13 Feb 2026.